Mizuho on Immatics (IMTX): 'BMS Cell Therapy Collaboration Discontinued, but No Material Impact; Stock Attractive Here'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: IMTX) | Delayed: 6.93 -0.14 (1.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.07 | 52 Week High | $ | |||
| Open | $7.25 | 52 Week Low | $ | |||
| Day High | $7.52 | P/E | N/A | |||
| Day Low | $6.90 | EPS | $ | |||
| Volume | 368,127 | |||||
